Nuwellis Boosts Gross Margins to 76% via Contract Manufacturing Shift
Event summary
- Nuwellis' gross margin improved to 76% in Q2 2026, up from 56% year-over-year.
- One-year anniversary of Aquadex production transition to KDI Manufacturing.
- Company reports $8.8M cash position as of August 31, 2026, with runway into Q3 2027.
- KDI delivered nearly 5,000 AquaFlexFlow blood circuits and 30 Aquadex SmartFlow consoles.
- Nuwellis maintained product quality and supply performance during transition.
The big picture
Nuwellis' strategic shift to contract manufacturing with KDI has significantly improved its financial profile, aligning with broader industry trends toward outsourced production for cost efficiency. The company's ability to maintain product quality while reducing costs positions it favorably in the competitive medical technology sector. The extended cash runway provides flexibility for strategic investments, but the challenge remains in balancing growth with financial discipline.
What we're watching
- Execution Risk
- Whether Nuwellis can sustain double-digit revenue growth while maintaining financial discipline.
- Operational Efficiency
- The pace at which contract manufacturing benefits scale across Nuwellis' product portfolio.
- Market Dynamics
- How the extended cash runway will impact Nuwellis' ability to invest in near-term growth initiatives.